AMGN | tickerfilter.com

Fundamental analysis

66%

Profitability 86%

Dept financing 44%

Liquidity 47%

Performance 56%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-3.62%

1 Month

-9.55%

3 Months

-9.90%

6 Months

-11.04%

1 Year

-13.81%

2 Year

14.13%

Key data

Stock price

$265.86

P/E Ratio

28.21

DAY RANGE

$265.66 - $273.48

EPS

$11.05

52 WEEK RANGE

$253.30 - $346.85

52 WEEK CHANGE

-$13.81

MARKET CAP

167.366 B

YIELD

2.93%

SHARES OUTSTANDING

537.706 M

DIVIDEND

$2.38

EX-DIVIDEND DATE

05-16-2025

NEXT EARNINGS DATE

08-05-2025

BETA

0.67

PUBLIC FLOAT

AVERAGE 10 VOLUME

$3,314,375

AVERAGE 30 VOLUME

$2,768,711

Company detail

CEO: Robert A. Bradway
Region: US
Website: amgen.com
Employees: 25,200
IPO year: 1984

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Its products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis. Repatha reduces the risks of myocardial infarction, stroke, and coronary revascularization.

AMGN - AMGEN INC